Do you want to read an article? Please log in or register.
Updates on ADCs in treatment of advanced breast cancer
Breast Cancer
SABCS 2024
Related content
SABCS 2024
Breast Cancer
Advancing Breast Cancer Treatment with Elacestrant
Breast Cancer
Optimizing treatment sequence for inoperable locally advanced breast cancer: Long-term outcomes of surgery first versus neoadjuvant chemotherapy in a real-world setting
Int J Cancer
Liu B, Song Y, Xu Y, Sun Q, Zhou Y, Lin Y
doi: 10.1002/ijc.35140
Breast Cancer
Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT study
Eur J Cancer
Tolosa P, Pascual T, Martínez-Saez O, Hernando C, Servitja S, Fernández Abad M, Brasó-Maristany F, Sanfeliu E, Benitez Fuentes JD, Lema L, Ruano Y, García-Fructuoso I, Parrilla L, Rodríguez A, Roncero AM, Cobos MÁ, Sánchez-Bayona R, Alva M, Madariaga A, Villacampa G, Canes J, Salvador F, Sánchez-Belmonte A, Malumbres M, Prat A, Ciruelos E
doi: 10.1016/j.ejca.2024.115219
Gastrointestinal Cancer
Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer Treatment: Insights from the TOPAZ-1 Trial
healthbook TIMES Onco Hema.
Fritsch R
doi: 10.36000/HBT.OH.2024.21.157
Breast Cancer
Postoperative radiotherapy in women with early operable breast cancer (Scottish Breast Conservation Trial): 30-year update of a randomised, controlled, phase 3 trial
Lancet Oncol
Williams LJ, Kunkler IH, Taylor KJ, Dunlop J, Piper T, Caldwell J, Jack W, Loane JF, Elder K, Bartlett JMS, Dixon JM, Cameron DA
doi: 10.1016/S1470-2045(24)00347-4
RECOMMENDED
Breast Cancer
Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update
★ 2
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
J Clin Oncol
Burstein HJ, DeMichele A, Fallowfield L, Somerfield MR, Henry NL, Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels, Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels for the Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panel
doi: 10.1200/JCO.24.00248
SPECIAL REPORT
Lung, Respiratory and Thoracic Cancer
Navigating the Evolving Treatment Paradigm for Advanced EGFR-mutated NSCLC
ESMO 2024
Breast Cancer
ABIGAIL: Abemaciclib plus endocrine therapy improves ORR versus paclitaxel in patients with advanced HR+/HER2- breast cancer with aggressive disease criteria
Breast Cancer
Second Primary Breast Cancer in Young Breast Cancer Survivors
JAMA Oncol
Brantley KD, Rosenberg SM, Collins LC, Ruddy KJ, Tamimi RM, Schapira L, Borges VF, Warner E, Come SE, Zheng Y, Kirkner GJ, Snow C, Winer EP, Partridge AH
doi: 10.1001/jamaoncol.2024.0286